Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 9/20 | 0.93 |
| ▸ | CCNH | P51946 | 9/20 | 0.93 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.93 |
| ▸ | CDK2 | P24941 | 5/20 | 0.85 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.85 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.85 |
| ▸ | CDK9 | P50750 | 1/20 | 0.85 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.85 |
| ▸ | MELK | Q14680 | 2/20 | 0.72 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.72 |
| ▸ | PAK4 | O96013 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741187 | 1.00 | CDK7 (0.93) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20754426 | 0.96 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741135 | 0.96 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878700 | 0.92 | CDK7 (0.80) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741190 | 0.92 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878720 | 0.92 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL18313535 | 0.87 | CDK7 (0.91) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741117 | 0.87 | CDK7 (0.91) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878808 | 0.87 | CDK7 (0.89) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17872121 | 0.87 | CDK7 (0.89) | CDK7CCNHMNAT1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021133601-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | CDK7 4/4885CCNH 40/4885MNAT1 1470/4885 |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 37/4885MNAT1 164/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CDK7 1/4885CCNH 45/4885MNAT1 110/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.